Walleye Trading
APLS

Walleye Trading’s Apellis Pharmaceuticals APLS Stock Holding History

Walleye Trading’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$362K Sell
9,000
-5,700
-39% -$123K ﹤0.01% 2780
2025
Q4 		$369K Sell
14,700
-4,600
-24% -$108K ﹤0.01% 3020
2025
Q3 		$437K Sell
19,300
-18,800
-49% -$438K ﹤0.01% 2831
2025
Q2 		$660K Buy
38,100
+12,500
+49% +$231K ﹤0.01% 2472
2025
Q1 		$560K Sell
25,600
-37,600
-59% -$1.04M ﹤0.01% 2443
2024
Q4 		$2.02M Buy
63,200
+10,300
+19% +$310K ﹤0.01% 1699
2024
Q3 		$1.53M Buy
52,900
+25,900
+96% +$959K ﹤0.01% 1849
2024
Q2 		$1.04M Sell
27,000
-11,400
-30% -$516K ﹤0.01% 2045
2024
Q1 		$2.26M Buy
38,400
+8,400
+28% +$535K ﹤0.01% 1663
2023
Q4 		$1.8M Sell
30,000
-23,700
-44% -$1.2M ﹤0.01% 2010
2023
Q3 		$2.04M Buy
53,700
+38,000
+242% +$1.67M 0.01% 1760
2023
Q2 		$1.43M Buy
15,700
+3,300
+27% +$285K ﹤0.01% 1900
2023
Q1 		$818K Sell
12,400
-32,800
-73% -$1.89M ﹤0.01% 2383
2022
Q4 		$2.34M Buy
45,200
+17,900
+66% +$949K 0.01% 1562
2022
Q3 		$1.86M Sell
27,300
-12,300
-31% -$728K 0.01% 1739
2022
Q2 		$1.79M Buy
39,600
+29,300
+284% +$1.34M 0.01% 1765
2022
Q1 		$523K Buy
+10,300
New +$455K ﹤0.01% 2873
2021
Q4 		– Sell
-20,700
Closed -$682K – 5307
2021
Q3 		$682K Buy
20,700
+13,500
+188% +$759K ﹤0.01% 2613
2021
Q2 		$455K Buy
+7,200
New +$372K ﹤0.01% 3027
2020
Q3 		– Sell
-18,500
Closed -$604K – 4061
2020
Q2 		$604K Buy
18,500
+7,200
+64% +$231K ﹤0.01% 2111
2020
Q1 		$303K Sell
11,300
-4,700
-29% -$167K ﹤0.01% 2280
2019
Q4 		$490K Buy
+16,000
New +$443K ﹤0.01% 2424

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Walleye Trading's APLS Position: Q1 2026 in Review

Walleye Trading reduced its Apellis Pharmaceuticals (APLS) stake by 48% in Q1 2026, selling an estimated $131K and leaving 6,602 shares worth $266K. The position accounts for ﹤0.01% of the portfolio, ranked #2949.

Walleye Trading first reported a position in APLS in Q1 2020 and has held it in 12 quarters since. The position peaked at $969K in Q3 2023. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Walleye Trading held 6,602 shares of Apellis Pharmaceuticals worth $266K as of Q1 2026.
  • Walleye Trading sold 6,097 Apellis Pharmaceuticals shares in Q1 2026, an estimated $131K.
  • Apellis Pharmaceuticals made up ﹤0.01% of Walleye Trading's portfolio in Q1 2026, its #2949 holding.
  • Walleye Trading first reported a position in Apellis Pharmaceuticals in Q1 2020 and has held it in 12 quarters since.
  • Walleye Trading's Apellis Pharmaceuticals position peaked at $969K in Q3 2023.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Walleye Trading's 13F filing for Q1 2026, filed 11 May 2026.